Objective: To determine the cost-effectiveness of recombinant human superoxide dismutase (rhSOD) in the prevention of chronic respiratory morbidity, defined as use of respiratory medications, in preterm infants.
Introduction
Despite clinical advances in antenatal and neonatal care resulting in improved mortality, extremely low birth weight infants remain at high risk for the development of bronchopulmonary dysplasia (BPD), a condition that affects approximately 20% of ventilated newborns and up to 85% of the most premature infants. 1 BPD is associated with the development of chronic respiratory morbidity (for example, asthma, repeated pulmonary infections) and significant neurodevelopmental delays.
Given its chronicity, and the vulnerable patient population in which it develops, BPD has important resource implications. The total annual expenditure for prematurity in the United States has recently been estimated at approximately 26 billion dollars. 2 Hospital costs for premature infants are highly variable and skewed, with the highest costs accruing to the smallest infants, who are also most likely to have the most severe respiratory disease. 3 Moreover, chronic respiratory illness appears to be a significant determinant of posthospital resource utilization, including hospital readmission. 4 Thus, therapies that reduce the frequency or acuity of postdischarge neonatal respiratory illness may have a significant impact on costs of care for this population.
A multicenter controlled trial previously reported the impact of one particular therapy, recombinant human copper-zinc superoxide dismutase (rhSOD), on the development of BPD and pulmonary outcome at 1 year corrected age in neonates 600 to 1200 g at birth. Although the trial revealed no significant impact on composite mortality or BPD using traditional definitions of oxygen requirement at 28 days or 36 weeks gestational age, secondary outcome measurements did show significantly improved clinical status at 1 year. In this cohort, a 36% reduction in the use of asthma medications was seen in rhSOD-treated infants (P ¼ 0.05). Findings were most significant in infants born p27 weeks gestation, in whom there was a 55% reduction in use of asthma medications (P ¼ 0.01), as well as a 55% reduction in emergency department visits and a 44% reduction in subsequent hospitalizations (P<0.05). 5 Despite the potential for antioxidant therapy to impact the resource-intensive condition of BPD, no cost analysis of the intervention has been completed. Our analysis therefore sought to determine the economic implications of rhSOD use in this population, using resource data collected during that randomized trial.
Methods

Overview of the SOD clinical trial
The rhSOD randomized controlled trial (RCT) enrolled 302 premature infants in 15 centers in the United States between January 1997 and June 1998. The study was previously reported and is summarized here briefly. 5 Of 274 infants who survived to discharge from hospital, 13 were known to have died in the first 2 years of life and 65 were lost to follow-up, so that 1 year follow-up data were available on 209 infants (80% of survivors at 1 year). Two of these infants had insufficient data on resource utilization; this economic evaluation was therefore completed on the 207 surviving infants and 28 infants who died before initial hospital discharge. Eligibility criteria included birth weight 600 to 1200 g, gestational age X24 weeks, postnatal age p24 h, and respiratory distress syndrome requiring oxygen, mechanical ventilation and exogenous surfactant treatment. Infants were excluded if they had major congenital anomalies, overwhelming congenital infection or severe perinatal asphyxia. Participants received either rhSOD or placebo intratracheally every 48 h while intubated, through 28 days of life. The primary outcome was death or oxygen dependency with radiographic changes consistent with BPD (based on Edwards score) at 28 days. Postdischarge secondary outcomes included presence of pulmonary illness that required treatment with asthma medications, as well as numbers of physician and emergency room visits and rehospitalizations.
Economic study design
The economic evaluation was undertaken ancillary to the previously completed rhSOD RCT and used patient-level data from the rhSOD study database. Analyses were performed from the perspective of a third party payer, with all relevant medical costs, both inpatient and outpatient, included. As direct nonmedical and productivity costs such as parental out-of-pocket travel expenses and wage losses were not included in the trial data collection, a broader, societal perspective was not undertaken. Costs and effects were included through follow-up at 1 year of age, consistent with the RCT. Approval was obtained from appropriate institutional review boards for both the original RCT and for the analysis of economic outcomes.
Resource utilization measurement and cost valuation
The study measured all relevant direct medical resource utilization from birth to discharge using resource data collected for infants from the clinical trial. Also measured were all relevant direct medical costs of pediatric care from discharge through 1 year, using data collected during the follow-up phase of the trial. The former included types and duration of respiratory support, days in hospital and ancillary resource use in hospital, whereas the latter included medication use postdischarge, number and type of physician's visits, and hospital readmissions.
Total costs per patient were the product of these resource quantities and unit costs. Each patient in the trial database had the number of days at each of four resource use levels determined: conventional ventilation, continuous positive airway pressure (CPAP), supplemental oxygen without mechanical ventilation or CPAP and no respiratory support. Direct medical costs for each of these resource levels were derived from charges in a separate billing database for a similar population of infants, and converted to costs using cost-center specific Medicare cost to charge ratios. 6 These unit costs were then applied to the measured resource counts in the trial to yield total inpatient costs per infant.
rhSOD is not currently commercially available, and therefore has no market price. For the economic evaluation it was set at $500 per dose based on preliminary discussions with the manufacturer, and the robustness of the conclusions to changes in this price was evaluated with a sensitivity analysis. rhSOD costs were included in the inpatient total costs. Outpatient medication prices were determined from market prices, 7 and included diuretics, oral electrolyte supplementation, bronchodilators, and oral and inhaled corticosteroids.
For all hospital readmissions, the national average daily charge for each disease related group diagnosis was obtained from the Association for Healthcare Research and Quality 2003 Kid's Inpatient Database. 8 Daily charges were converted to costs using hospital-specific Medicare cost to charge ratios and multiplied by readmission days per patient from the RCT. 6 Primary care and subspecialist visit costs, as well as emergency department costs, were derived from resource-based relative value units in the 1998 AAP primary care reimbursement survey and converted to costs using Medicare reimbursement rates. 9 Homecare costs per day for home ventilators, oxygen, monitors and nebulizers were obtained from market prices.
All costs were expressed in 2003 United States dollars. Where necessary, cost inputs from other years were converted to 2003 using the medical component of the Consumer Price index. 10 
Determination of effect
The economic evaluation is reported using similar outcomes to those used for the rhSOD RCT. Specifically, the analysis reports cost per death or BPD averted, as well as cost per infant with chronic respiratory morbidity averted. The latter was defined as the need for treatment of pulmonary illness with asthma medication including bronchodilators, diuretics or steroids.
Statistical considerations
Mean costs were compared between study arms using Student's t-test, whereas medians were compared using the Wilcoxon rank sum test. An adjusted analysis of costs was also undertaken, in which regression was performed on cost using general estimating equations, using the independent variables study arm, study center and gestational age. Log transformation of skewed cost values was undertaken before the parametric analysis.
Complete study data were available for all of the primary outcomes, for all of the predischarge resource utilization fields and for the majority of postdischarge resource utilization fields. When resource utilization data such as start and stop dates for medications were incomplete, we imputed duration of resource use using the mean value for remaining infants matched by gestational and postnatal age. The impact of this imputation was assessed in the regression analysis using imputation as an independent covariate, both separately and as an interaction term with study site. As noted above, 2 of 209 infants had insufficient resource utilization data to allow imputation; these infants were excluded.
To express costs and effects in a single metric, we calculated the incremental cost-effectiveness ratio, in which the difference in the mean cost for the rhSOD and control arms was divided by the difference in mean effects.
Uncertainty in the cost-effectiveness estimates was assessed using two approaches. Sampling uncertainty was assessed using nonparametric bootstrapping. 11, 12 This technique was performed on the 209 pairs of costs and outcomes in the original clinical trial cohort. From this sample, we chose 209 patients, replacing each one into the sample after the patient was chosen, so that infants could be represented more than once in the 'replication'. We then calculated the mean cost and mean effect, as well as the cost-effectiveness ratio. This experiment was then repeated 1000 times, and the resulting cost-effectiveness ratios were ranked, to give a distribution of costs, effects and ratios. We plotted these ratios on cost-effectiveness acceptability curves, which represent the probability that rhSOD treatment would be considered economically desirable for policy makers who were willing to pay between $0 and $150 000 per outcome (chronic respiratory morbidity, BPD, death) averted. 13 We also performed sensitivity analysis, in which alternative values for certain variables are used, and the effect on the final cost-effectiveness ratio determined. We performed sensitivity analysis using a range of 50 to 150% on inpatient hospital costs, inpatient physician costs and all outpatient cost variables, as well as prices for rhSOD ranging from $200 to $1000 per dose.
Results
Cost comparison Full cohort. As described in detail in the clinical trial report, and summarized in Table 1 for the cohort followed through 1 year, the study population characteristics were similar for both intervention and control groups for gestational age, birth weight, gender and race. There were no significant differences between the two groups for number of doses of study drug (rhSOD or placebo), days on the ventilator, days on CPAP and total days in hospital. For the entire cohort of infants, there were no statistically significant differences between the rhSOD and placebo groups with respect to mean inpatient costs, but there were trends toward lower costs for emergency room visits and rehospitalizations (Table 2 ). In regression analyses of log-transformed costs, with adjustment for gestational age, birthweight, study center and imputation, there was again no statistically significant difference between study arms (P ¼ 0.9). The covariate for imputation and for the interaction of imputation and study arm was nonsignificant, indicating that imputation did not significantly affect the results of the cost comparison, and that this effect was consistent across study arm.
<27 week cohort. More substantial cost differences were observed in the subgroup analysis of infants <27 weeks gestation at birth, those most susceptible to acute and chronic lung damage. For infants <27 weeks, mean costs for emergency room visits, rehospitalizations and outpatient medications were significantly lower in the rhSOD-treated group compared to the placebo controls ( Table 2 ). The point estimate for total cost was lower by $7641 in the rhSOD-treated group, but this difference was not statistically significant (P ¼ 0.70). As with the analysis of all infants, regression analysis of log-transformed costs using the covariates gestational age, birthweight, study center and imputation did not yield any significant differences.
Cost-effectiveness Full cohort. Point estimates for cost-effectiveness, before consideration of statistical uncertainty, are shown in Tables 3 and  4 for the short-term (composite death or BPD) and long-term (chronic respiratory morbidity) outcomes, respectively. These tables show the mean total cost per patient in each study arm (C), the differences in these costsFor incremental costFbetween study arms (DC), the mean effect in each study arm (E) and the difference in effectFor incremental effectFbetween study arms (DE). The incremental cost-effectiveness ratio (ICER) is calculated as the difference in incremental cost divided by the difference in incremental effect, as shown; it corresponds to the additional cost for each additional unit of effect. In these tables, the term 'dominated' refers to a therapy with higher costs and lower effects, whereas the term 'dominant' refers to a therapy with lower costs and improved effects. For the full cohort, rhSOD-treated infants did not have significantly lower mortality, BPD or cost savings in the short term. However, in longer term analysis using 1-year outcomes, rhSOD was associated with a highly favorable incremental cost of only $378 per chronic respiratory morbidity averted at 1 year corrected age. Figure 1 shows a plot of the mean cost and mean effectiveness for each of the 1000 bootstrap replications, reflecting the statistical uncertainty in our estimate of cost per chronic respiratory morbidity averted. As shown, 52% of the estimates are in the right lower quadrant, consistent with a 52% probability that treatment with rhSOD saves money and improves outcomes. Another 44% of the replications are in the upper right quadrant, consistent with higher costs and improved effectiveness, as seen with most health care interventions. Figure 2 shows a cost-effectiveness acceptability curve. This curve plots the probability that an intervention would be considered economically desirable by a decision maker who was willing to pay between $0 and $150 000 per case of chronic respiratory morbidity averted. The inflection point of this curve is at approximately 95% of replications and $7000 per case of chronic respiratory morbidity averted, indicating a 95% probability that the therapy would be considered cost-effective if a decision maker was willing to pay $7000 to avert one infant with long-term significant respiratory illness. This value corresponds to the traditional statistical test of significance at the a ¼ 0.05 level.
<27 week cohort. For the subgroup of infants <27 weeks gestational age, the point cost-effectiveness ratio shows that rhSODtreated infants had less respiratory morbidity and also lower costs, indicating that rhSOD therapy is 'dominant' or cost-saving. Through 1 year of age, infants <27 weeks again had lower mean costs and higher probability of being free of chronic respiratory morbidity, indicating that the therapy is also 'dominant' in this group. Indeed, the probabilistic analysis indicated that the probability that rhSOD both reduces costs and improves 1-year outcomes in this group of more vulnerable infants was 72%. 
Sensitivity analysis
Sensitivity analysis was performed to determine the impact on costeffectiveness of the cost per dose of rhSOD. As shown in Figure 3 , the point estimate for the incremental cost of rhSOD per case of chronic respiratory morbidity averted remains below $1000 even with per-dose costs exceeding $1000 (double the base case input).
Discussion
Although short-term effects of reducing death or BPD were not demonstrated by the rhSOD RCT, there is evidence that the antioxidant effects of rhSOD may have important clinical and resource implications that extend to 1 year corrected age, and perhaps beyond. This retrospective economic evaluation was undertaken ancillary to the clinical trial and used patient level data to quantify the cost implications of rhSOD therapy. It showed that rhSOD use in premature infants does not seem to significantly increase mean inpatient hospital costs, but may partially reduce outpatient costs. The point estimate for the incremental costeffectiveness was highly favorable at $378 per case of chronic respiratory morbidity averted at 1 year of age (the latter defined as use of asthma medications). There was a 52% probability that treatment with rhSOD would actually improve outcome and reduce costsFan uncommon occurrence in health careFand greater than 95% probability that treatment would be economically appealing to a decision maker who was willing to pay up to $7000 per case of chronic respiratory morbidity averted. These results were particularly pronounced in the subgroup of infants <27 weeks, in whom treatment with rhSOD had a 72% probability of improving outcome while at the same time reducing costs.
Comparison of these cost-effectiveness estimates to those of other therapies is problematic because of inconsistency in the choice of outcomes, costs or time horizons assessed in randomized trials in neonatology; in particular, no economic evaluations have been reported for trials using 1-year chronic respiratory morbidity as an outcome. For reference, representative studies have reported costeffectiveness ratios for extra-corporeal membrane oxygenation (d13 385 per life year saved), 14 inhaled nitric oxide for persistent pulmonary hypertension ($33 200 per survivor) 15 and universal hearing screening ($44 000 per case of hearing loss detected). 16 It should be emphasized that all of these interventions actually cost money to achieve better outcomes, as is the case more generally with health care in our society, which spends a large amount of money (approximately $1.7 trillion dollars per year, of which $26 billion is targeted to the treatment of prematurity) to maintain health and treat illness. Very few therapies indeed have been shown Abbreviations: C, cost; E, effectiveness; ICER, incremental cost-effectiveness ratio; SOD, superoxide dismutase.
Economic evaluation of SODto be cost saving; in neonatology, one of the few examples is surfactant for respiratory distress syndrome in preterm infants. 17 Thus, the cost-effectiveness determined for rhSOD may be considered potentially quite favorable. Asthma is associated with annual costs of up to $2 billion in school-aged children (1996 dollars) 18 and up to $5.8 billion in the entire US population (1994 dollars). 19 Although the nature of the long-term chronic respiratory morbidity reduced by rhSOD is not completely defined, it is plausible that its similarities to asthma would result in continued reductions in outpatient resource utilization beyond the time horizon for this study. In this case, rhSOD could be more economically desirable than we are able to estimate in this analysis. Moreover, there is some evidence from secondary analyses of the same trial data that rhSOD treatment may reduce the incidence of retinopathy of prematurity. 20 Any such impact would likely have a substantial and favorable effect on the cost-effectiveness of the drug.
Certain limitations of this analysis should be noted. First, it was a retrospective analysis of data collected from a trial that did not include a prospectively planned economic evaluation. Thus, the trial was not originally powered for analysis of cost outcomes, which are typically skewed and associated with higher variance. This deficiency may have resulted in our inability to detect a significant difference in costs in univariate analyses. Rather than relying on such hypothesis testing, we addressed this concern by estimating cost-effectiveness using the framework of the cost-effectiveness acceptability curve, which captures the statistical uncertainty associated with the joint distribution of costs and effects. 13, 21 The retrospective analysis also resulted in some Probability ICER within Acceptable Range $140 000 $120 000 $100 000 $80 000 $60 000 $40 000 $20 000 Figure 2 Cost-effectiveness acceptability curve for superoxide dismutase (SOD) as compared to placebo. The curve shows the proportion of bootstrap replications in which the cost-effectiveness of SOD was at or below the willingness-to-pay thresholds on the horizontal axis, corresponding to the probability that the therapy would be economically desirable to decision makers with those thresholds. missing data for start and stop dates of medications. However, we confirmed with regression that the resulting imputation did not significantly impact our cost estimates. In addition to incomplete data on some infants, the clinical trial had 20% loss to follow-up among surviving infants. Unfortunately, the presence or direction of resulting bias is not known, but this should not affect the conclusions of the economic evaluation more than it did the original trial. Finally, economic evaluation should ideally take a broader societal perspective, in which all costs and effects are considered, rather than just those accruing to third-party payers. 22 The study database contained information about direct medical costs, but additional items such as parental wage losses or out-of-pocket expenses for child care or transportation could not be added retrospectively.
Changes in certain aspects of neonatal care because the original trial was completed 10 years ago, such as increased use of CPAP, might reduce the background incidence of BPD and thereby affect the cost-effectiveness of rhSOD. In this regard, Smith et al. determined that, although there was a decreasing trend for severe BPD between 1994 and 2002, the odds of any BPD remained constant. 23 Although further clinical evaluation of rhSOD in the current era would be desirable, we are therefore cautiously optimistic that our results will remain relevant.
Another set of limitations relates to the completion of this analysis alongside a randomized trial. In certain circumstances, care provided in the context of such a trial may not be generalizable to a nontrial setting. The trial also used a somewhat short, 1-year time horizon, beyond which there may continue to be differences in resource utilization for chronic illnesses. Despite these considerations, we chose not to model outcomes outside the trial setting due to the significant assumptions that would be required for such a decision analysis. 24 Given that care other than rhSOD therapy was not prescribed by the study protocol and that the trial took place in multiple settings, we believe that the results have acceptable external validity; however, postmarket validation of this assumption should be undertaken following further clinical trials and possible Food and Drug Administration approval.
Finally, as rhSOD is not available commercially, the price per dose must be considered only an initial estimate. Our sensitivity analysis showed that the cost-effectiveness of rhSOD therapy for prevention of the longer-term pulmonary sequelae remains acceptable even with significantly higher unit costs for the drug.
In summary, this retrospective analysis supports the potential economic desirability of rhSOD treatment. Future clinical trials are likely to be undertaken before regulatory approval for clinical use. These trials should include prospectively planned economic evaluations, to capture a broader range of costs important to a societal perspective, over a longer time horizon and with consideration of the resource implications of neurosensory outcomes.
